纤维化间质性肺疾病中EQ-5D-5L与EQ-VAS的最小重要差异
本研究基于加拿大肺纤维化注册队列中1816例纤维化间质性肺疾病患者,评估EQ-5D-5L问卷的效度、内部一致性和反应性,并计算EQ-5D-5L及其视觉模拟量表(EQ-VAS)的最小重要差异(MID)。结果显示EQ-5D-5L与呼吸困难及生活质量问卷强相关,与肺功能检查弱相关;锚定法和分布法得到的MID范围不同,但各ILD亚型、性别和年龄间结果相似。
要点
- EQ-5D-5L在纤维化ILD患者中效度良好,与呼吸困难和生活质量问卷强相关。
- 锚定法估计EQ-5D-5L的MID为0.0050至0.054,EQ-VAS为0.5至5.0。
- 分布法估计EQ-5D-5L的MID为0.078至0.095,EQ-VAS为8.0至9.7。
核心结论
- 在大型多样化纤维化ILD队列中验证了EQ-5D-5L的效度并提出了EQ-5D-5L和EQ-VAS的MID,有助于未来临床试验设计和成本效果分析。
研究设计与样本
- 从前瞻性多中心加拿大肺纤维化注册队列中识别完成EQ-5D-5L的患者,评估效度、内部一致性和反应性,并计算MID。
- 共分析1816例患者,其中472例(26%)为特发性肺纤维化。
主要发现
- EQ-5D-5L评分与呼吸困难及其他生活质量问卷强相关,与肺功能检查弱相关。
- 锚定法估计EQ-5D-5L的MID范围为0.0050至0.054,EQ-VAS为0.5至5.0。
- 分布法(½SD和SEM)估计EQ-5D-5L的MID范围为0.078至0.095,EQ-VAS为8.0至9.7。
- 各ILD亚型、性别和年龄间结果相似。
关键数值与推荐
- EQ-5D-5L的MID:锚定法0.0050至0.054,分布法0.078至0.095。
- EQ-VAS的MID:锚定法0.5至5.0,分布法8.0至9.7。
临床怎么用
- EQ-5D-5L可用于纤维化ILD患者的生活质量评估,其MID值可辅助解读临床研究中的变化。
- EQ-VAS的MID值可用于成本效果分析中质量调整生命年的计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: The European Quality of Life 5-Dimensions 5-Levels questionnaire (EQ-5D-5L) is a multidimensional patient-reported questionnaire that supports calculation of quality-adjusted life-years. Our objectives were to demonstrate feasibility of use and to calculate the minimum important difference (MID) of the EQ-5D-5L and its associated visual analogue scale (EQ-VAS) in patients with fibrotic interstitial lung disease (ILD). METHODS: Patients who completed the EQ-5D-5L were identified from the prospective multicentre CAnadian REgistry for Pulmonary Fibrosis. Validity, internal consistency and responsiveness of the EQ-5D-5L were assessed, followed by calculation of the MID for the EQ-5D-5L and EQ-VAS. Anchor-based methods used an unadjusted linear regression against pulmonary function tests (PFTs) and dyspnoea and other quality of life questionnaires. Distribution-based method used one-half SD and SE measurement (SEM) calculations. RESULTS: 1816 patients were analysed, including 472 (26%) with idiopathic pulmonary fibrosis. EQ-5D-5L scores were strongly correlated with the dyspnoea and other quality of life questionnaires and weakly associated with PFTs. The estimated MID for EQ-5D-5L ranged from 0.0050 to 0.054 and from 0.078 to 0.095 for the anchor-based and distribution-based methods, respectively. The MID for EQ-VAS ranged from 0.5 to 5.0 and from 8.0 to 9.7 for the anchor-based and distribution-based methods. Findings were similar across ILD subtypes, sex and age. CONCLUSION: We used a large and diverse cohort of patients with a variety of fibrotic ILD subtypes to suggest validity and MID of both the EQ-5D-5L and EQ-VAS. These findings will assist in designing future clinical trials and supporting cost-effectiveness analyses of potential treatments for patients with fibrotic ILD.
引用
- Tsai APY, Hur SA, Wong A, et al. Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax. 2020. PMID: 33023996. doi:10.1136/thoraxjnl-2020-214944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。